Kato Takao, Kameoka Shingo, Kimura Tsunehito, Tanaka Shinichi, Nishikawa Toshio, Kobayashi Makio
Anticancer Res. 2002 Mar-Apr;22(2B):1105-12.
This study was designed to evaluate the prognostic importance of p53, mitosis, apoptosis and necrosis with long-term follow-up in Japanese patients with breast cancer. Four hundred and twenty-two patients with breast cancer were studied. We investigated 7 factors, including p53, mitotic index (MI), apoptotic index (AI), necrosis, lymph-node status (n), clinical tumor size (T) and lymphatic vessel invasion, followed for a median of 10 years. p53 accumulation was found in 30.1%, MI in 35.2%, AI in 36.3% and necrosis in 38.5%. p53 accumulation was correlated with MI (p = 0.0324), AI (p = 0.0010), necrosis (p = 0.0003), T (p = 0.0320), n (p < 0.0001), estrogen receptor (p = 0.0005) and progesterone receptor (p = 0.0287). Univariate analysis showed that p53, MI and necrosis were significantly predictive of 20-year overall survival (OS) or of 20-year relapse-free survival (RFS) (p < 0.0001 or p = 0.0003, p< 0.0001 or p < 0.0001 and p = 0.0131 or p = 0.0068, respectively), but AI was not. Multivariate analysis showed that p53 was an independent prognostic factor with RFS in all the patients, especially, with relapse-free survival (RFS) in the patients with T1 and with RFS and overall survival (OS) in the patients with a node-negative tumor. MI was an independent prognostic factor with OS in all the patients and with RFS and OS in the patients with a node-negative tumor. However, AI and necrosis were not independent predictors.
本研究旨在通过对日本乳腺癌患者的长期随访,评估p53、有丝分裂、细胞凋亡和坏死的预后重要性。对422例乳腺癌患者进行了研究。我们调查了7个因素,包括p53、有丝分裂指数(MI)、凋亡指数(AI)、坏死、淋巴结状态(n)、临床肿瘤大小(T)和淋巴管侵犯,随访时间中位数为10年。发现p53蓄积率为30.1%,MI为35.2%,AI为36.3%,坏死为38.5%。p53蓄积与MI(p = 0.0324)、AI(p = 0.0010)、坏死(p = 0.0003)、T(p = 0.0320)、n(p < 0.0001)、雌激素受体(p = 0.0005)和孕激素受体(p = 0.0287)相关。单因素分析显示,p53、MI和坏死对20年总生存率(OS)或20年无复发生存率(RFS)具有显著预测价值(分别为p < 0.0001或p = 0.0003,p < 0.0001或p < 0.0001,以及p = 0.0131或p = 0.0068),但AI并非如此。多因素分析显示,p53是所有患者无复发生存的独立预后因素,特别是T1期患者的无复发生存以及淋巴结阴性肿瘤患者的无复发生存和总生存。MI是所有患者总生存的独立预后因素,也是淋巴结阴性肿瘤患者无复发生存和总生存的独立预后因素。然而,AI和坏死并非独立预测因素。